IL 15 Human
(a) Analysis by RP-HPLC.
(b) Analysis SDS-PAGE.
Description
Interleukin-15 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 114 amino acids and having a molecular mass of 12.9kDa.
The IL-15 is purified by proprietary chromatographic techniques.
Product Specs
Recombinant human interleukin-15, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 114 amino acids. It has a molecular mass of 12.9 kDa.
The purification of IL-15 is achieved using proprietary chromatographic techniques.
(a) Reverse-phase high-performance liquid chromatography (RP-HPLC) analysis.
(b) Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
The ED50, determined using a cell proliferation assay with MO7e human megakaryocytic leukemic cells, is in the range of 0.3-2.6 ng/ml. This corresponds to a specific activity greater than 1.5 x 10⁷ U/mg.
NWVNVISDLK KIEDLIQSMH IDATLYTESD VHPSCKVTAM KCFLLELQVI SLESGDASIH DTVENLIILA NNSLSSNGNV TESGCKECEE LEEKNIKEFL QSFVHIVQMF INTS.
Product Science Overview
IL-15 was first identified in 1994 as a cytokine that shares many biological activities with IL-2, but it is produced by a wide variety of cell types, including monocytes, macrophages, and dendritic cells . The human recombinant form of IL-15 (rhIL-15) is a non-glycosylated monomer with a molecular weight of approximately 13 kDa, produced using recombinant DNA technology in E. coli .
IL-15 is essential for the survival and proliferation of NK cells and memory CD8+ T cells. It promotes the differentiation and activation of these cells, enhancing their cytotoxic activity against infected or malignant cells . IL-15 also plays a role in the homeostasis of T cells and the maintenance of long-term immune memory .
The potential of IL-15 in cancer immunotherapy has garnered significant interest. IL-15 agonists have shown promising results in preclinical studies, demonstrating their ability to inhibit tumor growth and prevent metastasis . Recombinant human IL-15 has been evaluated in clinical trials for its efficacy in treating various cancers, including chronic lymphocytic leukemia (CLL) and other lymphoid malignancies .
In a Phase I trial, administration of rhIL-15 as a continuous intravenous infusion was associated with a substantial increase in the number of NK cells, indicating its potential to enhance the efficacy of monoclonal antibody therapies . The combination of rhIL-15 with other immunotherapeutic agents, such as obinutuzumab, is being explored to improve treatment outcomes for patients with relapsed and refractory CLL .
Despite its potential, the clinical application of IL-15 faces challenges, including the identification of optimal dosing regimens and the management of potential toxicities . Ongoing research aims to address these challenges and further elucidate the mechanisms by which IL-15 can be harnessed for cancer immunotherapy .
